Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1205908 | 0.89 | OPRM1 (0.61) | OPRM1DRD4OPRL1OPRK1OPRD1 | |
| SCHEMBL17888202 | 0.86 | OPRL1 (0.53) | OPRM1DRD4OPRL1OPRK1OPRD1 | |
| SCHEMBL12049753 | 0.84 | OPRM1 (0.44) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL1427379 | 0.83 | OPRM1 (0.43) | OPRM1DRD4OPRL1OPRK1OPRD1 | |
| SCHEMBL9966015 | 0.81 | OPRM1 (0.48) | OPRM1DRD4OPRL1OPRK1OPRD1 | |
| SCHEMBL12363963 | 0.78 | OPRM1 (0.51) | OPRM1GRIN1GRIN2AOPRL1OPRK1 | |
| SCHEMBL10642751 | 0.78 | OPRL1 (0.53) | OPRM1GRIN1GRIN2AOPRL1OPRK1 | |
| SCHEMBL10643008 | 0.78 | OPRL1 (0.47) | OPRM1DRD4OPRL1OPRK1OPRD1 | |
| SCHEMBL5463873 | 0.78 | PRMT5 (0.47) | GRIN1GRIN2AOPRK1OPRD1HSD11B1 | |
| SCHEMBL153569 | 0.77 | OPRL1 (0.59) | OPRM1DRD4OPRL1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3262036-B1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20200325128-A1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | Argonaut Therapeutics Limited (GB) | 2020-10-15 | — | — | US | disclosed |
| WO-2016138114-A1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-8247401-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325128-A1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | PRMT5, PRMT6, PRMT1 | OPRM1 4536/4885DRD4 4671/4885GRIN1 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.